8-K: Celldex Therapeutics Reports Year-End 2024 Financial Results and Provides Corporate Update

Celldex Therapeutics announces its fourth quarter and year-end 2024 financial results, highlighting progress in its clinical programs, particularly barzolvolimab, and the initiation of a Phase 1 study for CDX-622.

Summary

• Celldex Therapeutics reported its financial results for the fourth quarter and year ended December 31, 2024.
• The company is actively enrolling patients in Phase 3 trials for barzolvolimab in chronic spontaneous urticaria (CSU).
• A Phase 3 program in chronic inducible urticaria (CIndU) is under development and expected to start in 2025.
• The Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE) is fully accrued.
• A Phase 2 study in atopic dermatitis was initiated, and enrollment is ongoing in a Phase 2 study in prurigo nodularis (PN).
• Celldex initiated a Phase 1 study for its first bispecific antibody for inflammatory diseases, CDX-622.
• Multiple data readouts are anticipated in 2025 from barzolvolimab Phase 2 studies and the CDX-622 Phase 1 study.
• Cash, cash equivalents, and marketable securities totaled $725.3 million as of December 31, 2024.
• Total revenue was $1.2 million for the fourth quarter and $7.0 million for the year ended December 31, 2024.
• Research and development expenses were $46.9 million for the fourth quarter and $163.6 million for the year ended December 31, 2024.
• General and administrative expenses were $10.3 million for the fourth quarter and $38.5 million for the year ended December 31, 2024.
• Net loss was $47.1 million, or ($0.71) per share, for the fourth quarter of 2024, and $157.9 million, or ($2.45) per share, for the year ended December 31, 2024.
• Celldex believes its current cash position is sufficient to fund operations through 2027.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with promising clinical trial results and a strong cash position, but also acknowledges financial losses and inherent risks in drug development.

Positives

• Barzolvolimab demonstrated a 71% complete response rate at Week 52 in a Phase 2 CSU study, showing a deepening of response over time.
• Barzolvolimab is the first drug to demonstrate clinical benefit in patients with chronic inducible urticaria in a large, randomized, placebo-controlled study.
• The company's cash position of $725.3 million is expected to fund operations through 2027.
• The initiation of a Phase 1 study for CDX-622 expands Celldex's pipeline and leadership in mast cell science.

Negatives

• The company reported a net loss of $47.1 million for the fourth quarter of 2024 and $157.9 million for the year.
• Revenue decreased in the fourth quarter of 2024 compared to the same period in 2023, primarily due to a decrease in services performed under manufacturing and R&D agreements with Rockefeller University.

Risks

• The company's ability to successfully complete research, development, and commercialization of its drug candidates is subject to risks and uncertainties.
• Clinical testing and patient accrual for clinical trials are inherently uncertain.
• The company has limited experience in bringing programs through Phase 3 clinical trials.
• Obtaining regulatory approvals is subject to timing, cost, and uncertainty.
• The company's ability to obtain capital to meet its long-term liquidity needs is not guaranteed.

Future Outlook

Celldex believes its current cash position is sufficient to fund operations through 2027 and anticipates multiple data readouts in 2025 from its barzolvolimab and CDX-622 studies.

Management Comments

• In 2024, Celldex set a new bar for efficacy in chronic urticarias presenting best-in-disease data across both our Phase 2 studies in CSU and CIndU, said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex Therapeutics.
• Our Phase 3 studies in CSU have been met with great enthusiasm from the global medical community and are actively enrolling patients around the world.
• We look forward to building on this momentum later this year when we initiate our Phase 3 program in CIndU.
• We closed 2024 with the initiation of two new programs advancing barzolvolimab into its fifth indication, atopic dermatitis, and expanding our leadership in mast cell science with the introduction of our first inflammatory bispecific candidate into the clinic, CDX-622, which targets stem cell factor and TSLP.
• We expect 2025 will be a year of continued execution across our robust pipeline supported by important data from our barzolvolimab Phase 2 studies in CSU, CIndU and EOE and our CDX-622 Phase 1 study in healthy volunteers.

Industry Context

Celldex is focusing on mast cell biology and developing therapeutics for inflammatory, allergic, and autoimmune diseases, positioning itself in a competitive landscape with other biotechnology companies targeting similar indications.

Comparison to Industry Standards

• The 71% complete response rate with barzolvolimab in CSU at Week 52 is a high rate compared to other treatments in the field, such as Xolair (omalizumab), which has shown lower complete response rates in some studies.
• Barzolvolimab's demonstration of clinical benefit in CIndU is notable, as there are limited approved therapies for this condition, setting it apart from competitors.
• The initiation of a Phase 1 study for CDX-622, targeting SCF and TSLP, reflects a growing interest in bispecific antibodies for inflammatory diseases, similar to efforts by companies like Amgen and Regeneron.

Stakeholder Impact

• Shareholders: The financial results and clinical trial updates will impact shareholder value and investment decisions.
• Patients: Positive clinical trial results offer hope for new treatment options for chronic urticaria, atopic dermatitis, and other inflammatory diseases.
• Employees: The company's financial stability and pipeline progress impact employee morale and job security.
• Medical Community: The data from clinical trials will inform treatment strategies and contribute to the understanding of mast cell biology.

Next Steps

• Initiate a Phase 3 program in chronic inducible urticaria (CIndU) in 2025.
• Present 76-week data from the Phase 2 study in CSU in 2025.
• Present data through week 44 from the Phase 2 study in CIndU in 2025.
• Report data from the Phase 2 study in eosinophilic esophagitis (EoE) in 2025.
• Continue enrollment in the Phase 2 study in prurigo nodularis (PN).
• Continue enrollment in the Phase 2 study in atopic dermatitis (AD).
• Continue enrollment in the Phase 1 study for CDX-622.

Key Dates